Literature DB >> 4633387

Providencia stuartii sepsis: a new challenge in the treatment of thermal injury.

P W Curreri, H M Bruck, R B Lindberg, A D Mason, B A Pruitt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4633387      PMCID: PMC1355549          DOI: 10.1097/00000658-197302000-00001

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  6 in total

1.  CHANGING CONCEPTS IN BURN SEPSIS.

Authors:  J A MONCRIEF; C TEPLITZ
Journal:  J Trauma       Date:  1964-03

2.  Fatal pseudomonas infection in burned patients. A clinical, bacteriologic and anatomic study.

Authors:  E R RABIN; C D GRABER; E H VOGEL; R A FINKELSTEIN; W A TUMBUSCH
Journal:  N Engl J Med       Date:  1961-12-21       Impact factor: 91.245

3.  Antimicrobial susceptibility of enterobacteriaceae and nonfermenting gram-negative bacilli.

Authors:  J A Washington
Journal:  Mayo Clin Proc       Date:  1969-11       Impact factor: 7.616

4.  Control of experimental and clinical burn wounds sepsis by topical application of sulfamylon compounds.

Authors:  R B Lindberg; J A Moncrief; A D Mason
Journal:  Ann N Y Acad Sci       Date:  1968-08-14       Impact factor: 5.691

5.  Infections with Providence bacilli. A clinical and bacteriologic study.

Authors:  C O Solberg; J M Matsen
Journal:  Am J Med       Date:  1971-02       Impact factor: 4.965

6.  In vitro susceptibility of gram-negative bacilli to gentamicin.

Authors:  J A Washington; R E Ritts; W J Martin
Journal:  Mayo Clin Proc       Date:  1970-02       Impact factor: 7.616

  6 in total
  14 in total

1.  Evolution of an incompatibility group IncA/C plasmid harboring blaCMY-16 and qnrA6 genes and its transfer through three clones of Providencia stuartii during a two-year outbreak in a Tunisian burn unit.

Authors:  C Arpin; L Thabet; H Yassine; A A Messadi; J Boukadida; V Dubois; L Coulange-Mayonnove; C Andre; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

2.  Synergy between cephalosporin and aminoglycoside antibiotics against Providencia and Proteus.

Authors:  P J Hyams; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

3.  The contribution of a bacterially isolated environment to the prevention of infection in seriously burned patients.

Authors:  J F Burke; W C Quinby; C C Bondoc; E M Sheehy; H C Moreno
Journal:  Ann Surg       Date:  1977-09       Impact factor: 12.969

4.  A simple cost-saving measure: 2.5% mafenide acetate solution.

Authors:  Amir Ibrahim; Shawn Fagan; Tim Keaney; Karim A Sarhane; Derek A Hursey; Philip Chang; Rob Sheridan; Colleen Ryan; Ronald Tompkins; Jeremy Goverman
Journal:  J Burn Care Res       Date:  2014 Jul-Aug       Impact factor: 1.845

5.  Transferable urease activity in Providencia stuartii.

Authors:  R B Grant; J L Penner; J N Hennessy; B J Jackowski
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

6.  Nosocomial urinary tract infections caused by two O-serotypes of Providencia stuartii in one hospital.

Authors:  G R Whiteley; J L Penner; I O Stewart; P C Stokan; N A Hinton
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

7.  Prospective survey of fecal, urinary tract, and environmental colonization by Providencia stuartii in two geriatric wards.

Authors:  P M Hawkey; J L Penner; M R Potten; M Stephens; L J Barton; D C Speller
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

8.  Cross-protection of mice provided by active and passive immunization against experimental infections with virulent Proteus rettgeri and Providencia bacteria.

Authors:  J L Penner; G R Whiteley
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

9.  O serotyping of Providencia stuartii isolates collected from twelve hospitals.

Authors:  J L Penner; N A Hinton; I B Duncan; J N Hennessy; G R Whiteley
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

10.  Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics.

Authors:  K E Price; T A Pursiano; M D DeFuria
Journal:  Antimicrob Agents Chemother       Date:  1974-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.